It can be difficult to deliver proteins and other large molecules to muscle tissue. But 4s3 Bioscience Inc., of Medford, Mass., said it believes it has found a back door into those cells using its 3E10-targeting antibody along with the ENT2 nucleoside transporter, which is naturally enriched in skeletal muscle fibers.
Wowed by stunning Phase IIa results for nephrology candidate KAI-4169, Thousand Oaks, Calif.-based Amgen Inc. tendered an offer of $315 million in cash to buy KAI Pharmaceuticals Inc., of San Francisco.
A year makes all the difference. In March 2011, the FDA sent Amyvid (florbetapir) back to its manufacturer, Avid Radiopharmaceuticals Inc., a wholly owned subsidiary of Eli Lilly and Co. Inc., of Indianapolis, to develop a reader training program for interpretation of scans made with Amyvid.
It was a tumultuous day at the market for Spectrum Pharmaceuticals Inc. and Allos Therapeutics Inc., as investors responded simultaneously to news of the two companies' merger and the failure of Spectrum's cancer drug apaziquone in two Phase III trials.
For Cleveland BioLabs Inc., of Buffalo, N.Y., the question of the day was phrased by its vice president of pharmaceutical development, Ed Venkat, who asked, "Why did BARDA reject our white paper proposals?"
Nearly eclipsed by the lengthy approval process for Bydureon (exenatide once-weekly), Amylin Pharmaceuticals Inc.'s metreleptin (recombinant methionyl human leptin) in diabetes lipodystrophy may soon get its moment in the sun.
AlloCure Inc. raised $25 million for a Series B venture financing, welcoming new investor Lundbeckfond Ventures, as well as previous investors SV Life Sciences and Novo A/S.
The Genentech Inc. unit of Roche AG announced that its Phase III (EMILIA) trial of Immunogen Inc.-partnered asset trastuzumab emtansine (T-DM1) showed positive results. Patients randomized to treatment with T-DM1 had a significantly longer duration of progression-free survival than those receiving the control therapy, lapatinib plus capecitabine.
Merrimack Pharmaceuticals Inc., which has initiated six new clinical trials since August 2011, priced an initial public offering (IPO) of 14.3 million shares of common stock at $7 per share, for a total anticipated raise of about $100 million.
